Higher baseline serum magnesium levels are linked to a higher risk for cardiac events in HFmrEF/HFpEF, while empagliflozin treatment shows a lower risk for these events in those with higher magnesium.
SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ -- A newly published post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, ...
62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo in subset of patients in CARDEA with AKI The new data presented were ...
THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American ...
SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug ...
MILAN, Italy — The antisense oligonucleotide vupanorsen substantially reduces very low density lipoprotein (VLDL) and remnant cholesterol levels in patients with raised lipids despite statin therapy, ...
In a post-hoc analysis of the DELIVER trial, interictal periods were longer with VYEPTI compared to placebo and corresponded to higher patient-reported quality of life outcomes Individuals taking ...
Daratumumab-lenalidomide maintenance significantly increases MRD-negative conversion and reduces progression risk in multiple ...
Weight regain after discontinuation of tirzepatide was accompanied by a reversal of cardiometabolic improvements in a post-hoc analysis. For waist circumference, systolic blood pressure, and HbA1c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback